EpiCypher is offering five fully funded EpiTitan™ Histone Peptide Array Screening & Services Grants, for which applications are to be submitted by September 10, 2014. Applications will be reviewed by an independant scientific community.
Epigenetics is the study of heritable changes in phenotype that exhibit no underlying changes in DNA sequence. Over the past several years there has been a significant increase in the number of epigenetic regulators as clinical targets, including Histone Deacetylases (HDAC), Bromodomain Proteins (BET), DOT1L, and EZH2. A number of these targets have FDA-approved drugs, or are in late stage clinical trials, to inhibit their function, demonstrating the adoption of supporting patients with diseases involving epigenetic targets.
Epigenetic Grant Program from EpiCypher™
EpiCypher is offering five (5) grants to researchers for Histone peptide array applications that have significant impact on epigenetics research and development.
As part of the company’s continuing efforts to help researchers unlock biological mysteries, EpiCypher today announced they are offering five fully-funded Epigenetic Grants. The company will thus support projects that involve the study of the role of Histone modifications in physiologic or pathologic processes. For the studies selected, EpiCypher will provide EpiTitan™ histone peptide arrays and perform the histone modification screening services, and supply statistical analysis of protein or antibody binding profile. Projects elligible for the grant include any effort that involves the study of the role of histone modifiations in physiologic or pathologic processes.
“Understanding fundamental questions at the molecular level are one of the most exciting and important frontiers in biomedical science, and many answers will be found through the study of chromatin biology and epigenetics. The goal of these grants is to introduce researchers to the benefits of epigenetics and to incorporate this method into their research so they can experience its biological advantages first hand,” said Sam Tetlow, CEO of EpiCypher. “Projects should speak to the public health importance, the significance of the application and/or any clinical potential.”
Applications for the grant are due by September 10, 2014 and the awardees will be notified no later than September 29, 2014. Anticipated start date of the project is October 15, 2014; project period is through to May 2015.
Apply for the EpiCypher™ Epigenetic Grant Program now!
For full information about the program, including application requirements and materials, you’ll need to start by filling in the EpiCypher Grant Application Request Form.
Once the form is completed and submitted, you will be sent a secure link to download the application and the program overview, including key dates.
About EpiCypher™ – Pioneering the Science of Epigenetics™
EpiCypher is a US bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Pioneer in the field of epigenetics and chromatin biology, EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced Histone array currently available.
EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.
EpiCypher’s product range is provided to European Life Scientists through tebu-bio.
